These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 1300551)

  • 61. Effect rHuEpo on predialysis CRF patients: study of 45 cases.
    Islam S; Rahman H; Rashid HU
    Bangladesh Med Res Counc Bull; 2005 Aug; 31(2):83-7. PubMed ID: 16967814
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Clinical experience with Repotin, a locally produced recombinant human erythropoietin, in the treatment of anaemia of chronic renal failure in South Africa.
    Swanepoel CR; Moosa MR; Rowland GF; Meyers AM; Botha BP; Smart AJ; Goodman R; Schall R; Keogh HJ; Merrifield EH
    S Afr Med J; 1996 Oct; 86(10):1266-9. PubMed ID: 8955732
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Quantitative assessment of erythropoiesis in haemodialysis patients demonstrates gradual expansion of erythroblasts during constant treatment with recombinant human erythropoietin.
    Beguin Y; Loo M; R'Zik S; Sautois B; Lejeune F; Rorive G; Fillet G
    Br J Haematol; 1995 Jan; 89(1):17-23. PubMed ID: 7833259
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Hemodynamic effects of anemia correction by recombinant human erythropoietin in predialysis patients with renal failure.
    Sapojnikov M; Veksler A; Yagil Y; Kogan J; Turkot S; Boris G; Oren S
    Ren Fail; 2005; 27(2):199-203. PubMed ID: 15807186
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Retardation of hemodialysis by recombinant human erythropoietin in patients with chronic kidney disease].
    Kato F; Takeuchi N; Takenoshita E; Yuasa J; Isaka S; Fujii T; Suzuki S; Irie Y; Ogawa M; Ueda S
    Nihon Jinzo Gakkai Shi; 2010; 52(1):58-65. PubMed ID: 20166543
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effects of erythropoietin on trace elements in patients with chronic renal failure undergoing hemodialysis.
    Hosokawa S; Yoshida O
    Nephron; 1993; 65(3):414-7. PubMed ID: 8289992
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Human recombinant erythropoietin (rHuEPO) in the treatment of anemia in patients with chronic renal failure (CRF): experience with a group of patients on chronic haemodialysis treatment.
    Ramírez B; Flores A; Pérez F; Córdoba C; García L; Vázquez G
    Transplant Proc; 1991 Apr; 23(2):1833-4. PubMed ID: 2053170
    [No Abstract]   [Full Text] [Related]  

  • 68. Occult infection and resistance of anaemia to rHuEpo therapy in renal failure.
    Muirhead N; Hodsman AB
    Nephrol Dial Transplant; 1990; 5(3):232-4. PubMed ID: 2113653
    [No Abstract]   [Full Text] [Related]  

  • 69. Effect of purified recombinant human erythropoietin on anemia in rats with experimental renal failure induced by five-sixth nephrectomy.
    Kawamura A; Higuchi M; Imai N; Kawaguchi T; Ogura Y
    Biotherapy; 1990; 2(1):77-85. PubMed ID: 2400629
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Erythropoietin-beta in the treatment of anemia in patients with chronic renal insufficiency].
    Dimković N
    Med Pregl; 2001; 54(5-6):235-40. PubMed ID: 11759218
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Anemia and its treatment in peritoneal dialysis patients].
    Hörl WH
    Wien Klin Wochenschr; 2005; 117 Suppl 6():69-72. PubMed ID: 16437336
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The long-term effects of recombinant human erythropoietin on the cardiovascular system.
    Eschbach JW; Aquiling T; Haley NR; Fan MH; Blagg CR
    Clin Nephrol; 1992; 38 Suppl 1():S98-103. PubMed ID: 1295715
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Renal disease. II. The clinical impact of recombinant human erythropoietin.
    Muirhead N
    J R Coll Physicians Lond; 1997; 31(2):125-30. PubMed ID: 9131506
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure.
    Hayashi T; Suzuki A; Shoji T; Togawa M; Okada N; Tsubakihara Y; Imai E; Hori M
    Am J Kidney Dis; 2000 Feb; 35(2):250-6. PubMed ID: 10676724
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Treatment of multiple myeloma associated anemia with human recombinant erythropoietin in a hemodialysis patient].
    Muszytowski M; Nowak J; Wojnicz M; Zalewska A; Ruszkiewicz-Fołda M
    Pol Arch Med Wewn; 1995 Jan; 93(1):77-9. PubMed ID: 7479222
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Iron management during treatment with recombinant human erythropoietin in chronic renal failure.
    Watson A
    J Clin Pharmacol; 1993 Dec; 33(12):1134-8. PubMed ID: 8126248
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Influence of erythropoietin treatment on gonadotropic hormone levels and sexual function in male uremic patients.
    Wu SC; Lin SL; Jeng FR
    Scand J Urol Nephrol; 2001 Apr; 35(2):136-40. PubMed ID: 11411657
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Resistance to recombinant human erythropoietin in hemodialysis patients.
    Drüeke TB
    Am J Nephrol; 1990; 10 Suppl 2():34-9. PubMed ID: 2260616
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Hematopoietic effect of Radix angelicae sinensis in a hemodialysis patient.
    Bradley RR; Cunniff PJ; Pereira BJ; Jaber BL
    Am J Kidney Dis; 1999 Aug; 34(2):349-54. PubMed ID: 10430986
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Use of recombinant erythropoietin in a pregnant renal transplant recipient.
    Thorp M; Pulliam J
    Am J Nephrol; 1998; 18(5):448-51. PubMed ID: 9730574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.